Literature DB >> 6125172

The effect of intrinsic sympathomimetic activity of beta-adrenoceptor blockers on circadian heart rate.

P Fitscha, B Tiso, W Meisner, D Spitzer.   

Abstract

1 The effect of a beta-adrenoceptor blocker without intrinsic sympathomimetic activity (propranolol) and a beta-adrenoceptor blocker with ISA (pindolol) on circadian heart rate was studied in 10 patients (3 women and 7 men) with an average age of 55 years and the following diagnoses: coronary heart disease (n = 7) and hypertension (n = 3). The therapy was carried out in a randomized, cross-over study, with 3 x 40 mg propranolol and 3 x 5 mg pindolol. 2 Propranolol lowered the averaged circadian heart rate significantly (P less than 0.001) from 78 to 68 beats/min. The rate decreased both during the day and at night and the reduction was greater the higher the control value. The minimal hourly heart rate also decreased significantly (P less than 0.005) from 65 to 69 beats/min. 3 After pindolol the averaged circadian heart rate was not markedly changed. It reached a stable rate of around 70 beats/min. At a heart rate of below 70 beats/min an increase in rate was observed, whereas above 70 beats/min a reduction was found. The mean heart rate during the day remained unchanged. There was a significant relationship between the level of the control heart rate and the decrease in rate (r = 0.85, P less than 0.005). 4 In a bicycle exercise test of 1 Watt/kg body weight over a period of 6 min, both beta-adrenoceptor blockers lowered blood pressure and heart rate to the same extent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125172      PMCID: PMC1402163          DOI: 10.1111/j.1365-2125.1982.tb01913.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Investigations with beta-adrenoceptor blocking drugs in healthy volunteers.

Authors:  W H Aellig
Journal:  Acta Med Scand Suppl       Date:  1977

2.  Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89,406 in healthy volunteers.

Authors:  T L Svendsen; O Hartling; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

3.  Comparative investigation of the respiratory and cardiovascular effect of mepindolol, propranolol and pindolol in asthmatic patients.

Authors:  H M Beumer; C Teirlinck; R A Wiseman
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-06

4.  Studies of cardioselectivity and partial agonist activity in beta-adrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise.

Authors:  V M Oh; C M Kaye; S J Warrington; E A Taylor; J Wadsworth
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

5.  Of senile cardiomyopathy.

Authors:  G E Burch
Journal:  Am Heart J       Date:  1979-07       Impact factor: 4.749

6.  Sleep and ventricular premature beats.

Authors:  B Lown; M Tykocinski; A Garfein; P Brooks
Journal:  Circulation       Date:  1973-10       Impact factor: 29.690

7.  The regulation of heart rate during sleep.

Authors:  W Baust; B Bohnert
Journal:  Exp Brain Res       Date:  1969       Impact factor: 1.972

8.  A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.

Authors:  J J McNeil; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

9.  Clinical pharmacology of adrenergic-blocking drugs.

Authors:  W J Louis; M J Rand; J J McNeil; O Drummer; B Jarrott
Journal:  Cardiology       Date:  1979       Impact factor: 1.869

10.  Comparison of metoprolol and pindolol in the treatment of mild to moderate hypertension: a double-blind crossover study.

Authors:  J J McNeil; W J Louis; A E Doyle; F J Vajda
Journal:  Med J Aust       Date:  1979-05-19       Impact factor: 7.738

  10 in total
  5 in total

1.  Differential cardiovascular effects of propranolol, atenolol, and pindolol measured by impedance cardiography.

Authors:  S H Thomas; R C Cooper; M Ekwuru; S Fletcher; J Gilbody; T S Husseyin; M Ishaque; R Jagathesan; G Reddy; S E Smith
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Studies of the agonist and antagonist activity of cicloprolol in man.

Authors:  P M McCaffrey; M Burke; J G Riddell; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Effect on heart rate over 24 hours of pindolol administered for 14 days.

Authors:  J P Kantelip; J F Trolese; P G Cromarias; P Duchêne-Marullaz
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Electrophysiologic effects of intravenous xamoterol in patients with sinus node dysfunction.

Authors:  M de Marneffe; P Waterschoot; A Bernard; P Dubois; F Boujelben; I Liebens; M Englert
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

5.  Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.

Authors:  Shirin S Joseph; James A Lynham; Peter Molenaar; Andrew A Grace; William H Colledge; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-08       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.